|
||
(Exact name of registrant as specified in its charter)
|
||
|
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
(Former name or former address, if changed since last report.)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Exhibit No.
|
|
Description
|
|
Opinion of Morgan, Lewis & Bockius LLP
|
|
|
Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.1)
|
|
|
Press Release of the Company, dated December 9, 2022
|
|
104
|
|
Cover Page Interactive Data File (embedded with the Inline XBRL document)
|
December 9, 2022
|
ADMA Biologics, Inc.
|
||
|
|
||
|
By:
|
/s/ Brian Lenz
|
|
|
|
Name:
|
Brian Lenz
|
|
|
Title:
|
Executive Vice President and Chief Financial Officer
|
Re: |
ADMA Biologics, Inc. Registration Statement on Form S-3 (333-256643)
|
|
Morgan, Lewis & Bockius llp |
|
502 Carnegie Center |
![]() |
|
Princeton, NJ 08540-6241 |
![]() |
|
United States
|
Very truly yours,
/s/ Morgan, Lewis & Bockius LLP |
Document and Entity Information |
Dec. 09, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Dec. 09, 2022 |
Entity File Number | 001-36728 |
Entity Registrant Name | ADMA BIOLOGICS, INC. |
Entity Central Index Key | 0001368514 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 56-2590442 |
Entity Address, Address Line One | 465 State Route 17 |
Entity Address, City or Town | Ramsey |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07446 |
City Area Code | 201 |
Local Phone Number | 478-5552 |
Title of 12(b) Security | Common Stock |
Trading Symbol | ADMA |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
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end
,CC:1O][8X/68:NV /JI4.<_.T J2\'*&."1X=(U<[X
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M.AB6ZSN&O015:QZ'@D5,RB66G1Q)5=;.E)*"KI%2;>V!D*/(!:E5_3!V6^X;N$Z#0(6. %QB80]O P8]/G
M0J7F=BUNP%/A:E/3##0<^3:F#B;$]&S#"H/0!3,F/HDBEN[.F7&%G'98FSEBW9'U4)E-+H;,9/H$*,7%+%F
@VZ7L?JS>KT3F4[H&,V5NUT#CNJR@W(6QI)3*L%N)J>
M-,(&4>S&G6T=*,>;44;]J8]*3SGB\X58R+(".$-%(N''[^Y\G,2=!&Y@79S4
MR,R13[